Incorporated in 2001, Sai Parenteral’s Ltd. is a diversified pharmaceutical formulations company with expertise in research, development, and manufacturing.
The company operates in two segments: Branded Generic Formulations and Contract Development and Manufacturing Organisation (CDMO) products and services for domestic and international markets.
The product portfolio spans multiple therapeutic areas including cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements (VMS), analgesics, and dermatology. Offerings are across dosage forms such as injectables, tablets, capsules, liquid orals, and ointments.
Sai Parenteral’s serves a wide customer base comprising central and state government agencies, pharmaceutical companies, public and private hospitals, and super stockists in India. The company entered exports in FY 2023 after acquiring two internationally accredited facilities in Hyderabad, Telangana, and now supplies to regulated and semi-regulated markets in Australia, New Zealand, Southeast Asia, the Middle East, and Africa.
The company owns and operates five manufacturing facilities in India. Four are located in Hyderabad, Telangana, comprising a GMP-compliant injectable unit, a WHO-GMP injectable unit, a TGA-Australia and PIC/S accredited solid oral dosage unit, and a WHO-GMP cephalosporin facility. Its wholly owned subsidiary, Revat Laboratories, operates a GMP-certified facility in Ongole, Andhra Pradesh.
As of December 31, 2025, Sai Parenteral Ltd. employed 298 full-time employees.
Competitive Strength:
| Period Ended | 30 Sep 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 376.24 | 272.39 | 268.10 | 133.96 |
| Total Income | 89.43 | 163.74 | 155.18 | 97.03 |
| Profit After Tax | 7.76 | 14.43 | 8.42 | 4.38 |
| EBITDA | 16.24 | 39.44 | 31.70 | 17.64 |
| NET Worth | 209.37 | 95.78 | 76.40 | 31.49 |
| Reserves and Surplus | 188.84 | 80.36 | 61.30 | 24.34 |
| Total Borrowing | 76.07 | 93.95 | 118.79 | 68.55 |
| Amount in ₹ Crore | ||||
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Capacity expansion and upgradation of manufacturing facilities | 110.80 |
| 2 | Establishment of a new R&D Centre; | 18.02 |
| 3 | Repayment / prepayment of certain outstanding borrowings | 14.30 |
| 4 | Working capital requirements | 33.00 |
| 5 | Investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the proposed acquisition of Noumed Pharmaceuticals Pty Limited (Australia); and | 35.64 |
| 6 | General corporate purposes | |
| Total | 211.76 |
| KPI | Sep 30, 2025 | Mar 31, 2025 |
|---|---|---|
| ROE | 5.13% | 16.82% |
| ROCE | 9.28% | 28.92% |
| RoNW | 5.09% | 15.09% |
| PAT Margin | 8.93% | 8.88% |
| EBITDA Margin | 18.68% | 24.18% |
| Price to Book Value | 10.89 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (₹) | 5.43 | |
| P/E (x) | 72.19 |
| IPO Date | 24 to 27 Mar, 2026 |
| Listing Date | Thu, Apr 2, 2026T |
| Face Value | ₹5 per share |
| Price Band | ₹372 to ₹392 |
| Lot Size | 38 Shares |
| Sale Type | Fresh capital cum OFS |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Total Issue Size | 1,04,28,288 shares (agg. up to ₹409 Cr) |
| Fresh Issue | 72,70,408 shares (agg. up to ₹285 Cr) |
| Offer for Sale | 31,57,880 shares of ₹5 (agg. up to ₹124 Cr) |
| Share Holding Pre Issue | 3,69,08,823 shares |
| Share Holding Post Issue | 4,41,79,231 shares |
Anil Kumar Karusala, Vijitha Gorrepati and Karusala Aruna are company promoters.
| Share Holding Pre Issue | 61.23% |
| Share Holding Post Issue | 51.20% |
As per our analysis and Based on the information we have, this is the output.
Allah knows best.
If you find this result mistaken or questionable, let us know via email at info (@) halalstock.in
The IPO dashboard offers insights on the Latest Current & Upcoming IPOs in BSE & NSE. It also evaluates IPOs for Shariah compliance, ensuring alignment with Islamic principles for ethical investment choices.
Last Updated on April 10, 2026 Property Share Investment Trust REIT PropShare Celestia is the third scheme launched by Property Share Investment Trust, India’s first SEBI-registered small and medium REIT.
Last Updated on April 9, 2026 Om Power Transmission Ltd. IPO Incorporated in June 2011, Om Power Transmission Limited is a power transmission infrastructure engineering, procurement, and construction (EPC) company
Last Updated on April 1, 2026 Safety Controls & Devices Ltd. IPO Incorporated in June 2015, Safety Controls and Devices Limited specialises in EPC (Engineering, Procurement, and Construction), focusing on
You can contribute as little as
100, 200, 500 & so…
every bit counts.
